Selectivity and Maximum Response of Vibegron and Mirabegron for ß3-Adrenergic Receptors.
Curr Ther Res Clin Exp
; 96: 100674, 2022.
Article
em En
| MEDLINE
| ID: mdl-35693456
ABSTRACT
Background:
The ß3-adrenergic agonists vibegron and mirabegron have shown favorable safety profiles and efficacy for the treatment of overactive bladder. However, ß-adrenergic receptors are also found outside the bladder, which could lead to off-target activity.Objective:
This study assessed the selectivity of vibegron and mirabegron for ß-adrenergic receptors and the maximal effect and potency for ß3-adrenergic receptors.Methods:
Functional cellular assays were performed using Chinese hamster ovary-K1 cells expressing ß1-, Chinese hamster ovary cells expressing ß2-, and human embryonic kidney 293 cells expressing ß3-adrenergic receptors. Cells were incubated with vibegron, mirabegron, or control (ß1 and ß3, isoproterenol; ß2, procaterol). Responses were quantified using homogeneous time-resolved fluorescence of cyclic adenosine monophosphate and were normalized to the respective control. Half-maximal effective concentration and maximum response values were determined by nonlinear least-squares regression analysis.Results:
Activation of ß3-adrenergic receptors with vibegron or mirabegron resulted in concentration-dependent ß3-adrenergic receptor responses. Mean (SEM) half-maximal effective concentration values at ß3-adrenergic receptors were 2.13 (0.25) nM for vibegron and 10.0 (0.56) nM for mirabegron. At a concentration of 10 µM, ß3-adrenergic activity relative to isoproterenol was 104% for vibegron and 88% for mirabegron. Maximum response at ß3-adrenergic receptors was 99.2% for vibegron and 80.4% for mirabegron. ß1-adrenergic activity was 0% and 3% for vibegron and mirabegron, respectively; ß2-adrenergic activity was 2% and 15%, respectively.Conclusions:
Vibegron showed no measurable ß1 and low ß2 activity compared with mirabegron, which showed low ß1 and some ß2 activity. Both showed considerable selectivity at ß3-adrenergic receptors; however, vibegron demonstrated near-exclusive ß3 activity and a higher maximum ß3 response.
Texto completo:
1
Coleções:
01-internacional
Base de dados:
MEDLINE
Idioma:
En
Ano de publicação:
2022
Tipo de documento:
Article